Fluvastatin Extended-Release Tablets and Mavyret

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Glecaprevir may increase the blood levels of fluvastatin. This can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with fluvastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSE: Coadministration with glecaprevir-pibrentasvir may increase the plasma concentrations of all statins including fluvastatin and pitavastatin. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of statins by glecaprevir and pibrentasvir. Although the interaction has not been studied specifically with fluvastatin or pitavastatin, it has been reported with other statins that are also substrates of OATP1B1. High levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.

MANAGEMENT: Caution is advised during concomitant administration of fluvastatin or pitavastatin with glecaprevir-pibrentasvir. The lowest approved dosage of the statin should be used. If higher dosages are required, the lowest effective statin dosage should be prescribed based on a risk/benefit assessment.

Fluvastatin Extended-Release Tablets

Generic Name: fluvastatin

Brand name: Lescol, Lescol XL

Synonyms: Fluvastatin

What is Fluvastatin Extended-Release Tablets?

Mavyret

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: n.a.

What is Mavyret?